A phase 1 study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors.

被引：4
|
作者：
Hyman, David Michael
Brana, Irene
Spreafico, Anna
Schram, Alison M.
Pandya, Naimish B.
Hoffman, Kimberly
Hallet, Robin
Giblin, Patricia
Anido, Judit
Ruano, Isabel Huber
Wasserman, Robert
Magram, Jeanne
Siu, Lillian L.
Tabernero, Josep
Seoane, Joan
Baselga, Jose
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] UHN Princess Margaret Hosp, Cambridge, ON, Canada
[3] Princess Margaret Canc Ctr, Toronto, ON, Canada
[4] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA
[5] Northern Biol Inc, Toronto, ON, Canada
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.TPS2602
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS2602
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Initial results from the Phase I study of MSC-1, a humanized anti-LIF monoclonal antibody, in patients with advanced solid tumors
    Schram, Alison
    Spreafico, Anna
    Oliva, Marc
    Brana, Irene
    Garralda, Elena
    Lakhani, Nehal
    Von Hoff, Daniel
    Borazanci, Erkut
    Pandya, Naimish
    Hoffman, Kimberly
    Hallett, Robin
    Giblin, Patricia
    Anido, Judit
    Kelly, Adrianne
    Wasserman, Robert
    Seoane, Joan
    Siu, Lillian
    Hyman, David M.
    Tabernero, Josep
    CANCER RESEARCH, 2019, 79 (13)
  • [2] Phase I dose escalation of MSC-1, a humanized anti-LIF monoclonal antibody, in patients (pts) with advanced solid tumours: Updated results
    Borazanci, E.
    Schram, A.
    Brana, I.
    Vieito Villar, M.
    Garralda, E.
    Spreafico, A.
    Oliva, M.
    Lakhani, N.
    Wasserman, R.
    Hoffman, K.
    Hallett, R.
    Anido, J.
    Giblin, P.
    Pandya, N.
    Kelly, A.
    Seoane, J.
    Von Hoff, D. D.
    Siu, L. L.
    Hyman, D. M.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2019, 30
  • [3] LIF as a novel cancer immunotherapy target: modulating the tumor microenvironment with MSC-1, a humanized anti-LIF monoclonal antibody
    Magram, Jeanne
    Pandya, Naimish
    Hoffman, Kimberly
    Hallett, Robin
    Giblin, Patricia
    Sinclair, Angus
    Anido, Judit
    Ruano, Isabel Huber
    Sala, Ada
    Pascual, Monica
    Chigancas, Vanessa
    Wasserman, Robert
    Seoane, Joan
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [4] A phase 1 study of serplulimab, a novel humanized monoclonal anti-PD-1 antibody, in patients with advanced solid tumors.
    Ho, Ching-Liang
    Chao, Tsu-Yi
    Chang, Chia Lun
    Lin, Hsuan-Yu
    Yang, Futang
    Wang, Qingyu
    Zhu, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
    Borazanci, E.
    Schram, A. M.
    Garralda, E.
    Brana, I
    Villar, M. Vieito
    Spreafico, A.
    Oliva, M.
    Lakhani, N. J.
    Hoffman, K.
    Hallett, R. M.
    Maetzel, D.
    Hua, F.
    Hilbert, J.
    Giblin, P.
    Anido, J.
    Kelly, A.
    Vickers, P. J.
    Wasserman, R.
    Seoane, J.
    Siu, L. L.
    Hyman, D. M.
    Hoff, D., V
    Tabernero, J.
    ESMO OPEN, 2022, 7 (04)
  • [6] A phase 1 study of ABT-806, a humanized recombinant anti-EGFR monoclonal antibody, in patients with advanced solid tumors
    Cleary, James M.
    Yee, Lorrin Kwock-Chong
    Azad, Nilofer
    Carducci, Michael
    Cosgrove, David
    Limaye, Sewanti
    Gandhi, Leena
    Pedersen, Michelle
    Ansell, Peter
    Ames, William
    Sharma, Shringi
    Hsu, Ya-Hui
    Munasinghe, Wijith
    Reilly, Edward
    Holen, Kyle D.
    Humerickhouse, Rod
    CANCER RESEARCH, 2012, 72
  • [7] A phase 1 study of MEDI4736, an anti PD-L1 antibody, in patients with advanced solid tumors.
    Lutzky, Jose
    Antonia, Scott Joseph
    Blake-Haskins, Andy
    Li, Xia
    Robbins, Paul B.
    Shaiabl, Aiman M.
    Vasseill, Jim
    Ibrahim, Ramy A.
    Khleif, Samir
    Segal, Neil Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] A phase 1/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors.
    Ahnert, Jordi Rodon
    Taylor, Matthew H.
    O'Reilly, Eileen Mary
    Zhang, Jingsong
    Doebele, Robert Charles
    Ben, Yong
    Sharp, Leslie L.
    Boyle, William J.
    Chang, Cathy
    Frey, Gerhard
    Chen, Wei
    Melnick, Michael
    Short, Jay M.
    Burris, Howard A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] MSC-1 is a first-in-class humanized monoclonal antibody that modulates the tumor microenvironment by inhibiting a novel cancer immunotherapy target, LIF
    Sinclair, Angus
    Hallett, Robin
    Giblin, Patricia
    Huber-Ruano, Isabel
    Anido, Judit
    Pandya, Naimish
    Hoffman, Kimberly
    Sala, Ada
    Pascual, Monica
    Chigancas, Vanessa
    Raman, Swetha
    Fransson, Johan
    Julien, Jean-Philippe
    Wasserman, Robert
    Magram, Jeanne
    Seoane, Joan
    CANCER RESEARCH, 2018, 78 (13)
  • [10] A PHASE 1 STUDY OF NECITUMUMAB (ANTI-EGFR MONOCLONAL ANTIBODY) IN JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS
    Nokihara, Hiroshi
    Yamamoto, Noboru
    Tamura, Yosuke
    Tanabe, Yuko
    Honda, Kazunori
    Asahina, Hajime
    Enatu, Sotaro
    Kurek, Raffael
    Yamada, Yasuhide
    Tamura, Tomohide
    ANNALS OF ONCOLOGY, 2014, 25
12345